284.34
0.91 (0.32%)
| Penutupan Terdahulu | 283.43 |
| Buka | 283.50 |
| Jumlah Dagangan | 193,474 |
| Purata Dagangan (3B) | 579,657 |
| Modal Pasaran | 137,679,421,440 |
| Harga / Pendapatan (P/E TTM) | 32.35 |
| Harga / Pendapatan (P/E Ke hadapan) | 27.40 |
| Harga / Jualan (P/S) | 6.09 |
| Harga / Buku (P/B) | 5.24 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 Feb 2025 |
| Hasil Dividen (DY TTM) | 1.41% |
| Margin Keuntungan | 17.85% |
| Margin Operasi (TTM) | 19.02% |
| EPS Cair (TTM) | 8.73 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 10.10% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 29.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 62.80% |
| Nisbah Semasa (MRQ) | 2.17 |
| Aliran Tunai Operasi (OCF TTM) | 2.76 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 1.04 B |
| Pulangan Atas Aset (ROA TTM) | 6.56% |
| Pulangan Atas Ekuiti (ROE TTM) | 14.58% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (AU) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | CSL FPO [CSL] | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 1.38 |
|
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world’s second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Large Growth |
| % Dimiliki oleh Orang Dalam | 0.30% |
| % Dimiliki oleh Institusi | 37.01% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |